BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 5335879)

  • 1. Clinical evaluation of biperiden in Parkinson's disease.
    Strang RR
    Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease.
    Strang RR
    Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of biperiden in delayed-release form in the treatment of Parkinson's disease and parkinsonian syndromes of various etiologies. Clinical experiments].
    Puntoni U
    Clin Ter; 1983 Oct; 107(1):37-44. PubMed ID: 6653070
    [No Abstract]   [Full Text] [Related]  

  • 6. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of the Parkinson syndrome with amantadine].
    Hartmann-von Monakow K
    Schweiz Med Wochenschr; 1971 Dec; 101(48):1736-9. PubMed ID: 5140093
    [No Abstract]   [Full Text] [Related]  

  • 8. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
    Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
    Rosati G; Agnetti V; Mura F; Granieri E
    Minerva Med; 1974 May; 65(33):1811-23. PubMed ID: 4602058
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical aspects and drug therapy of Parkinson's syndrome].
    Mumenthaler M
    Schweiz Med Wochenschr; 1966 Apr; 96(15):479-84. PubMed ID: 4862148
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anticholinergic treatment of Parkinson's disease (author's transl)].
    Ascher PW
    Wien Klin Wochenschr; 1976 Oct; 88(19):641-6. PubMed ID: 790774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M; Barbeau A
    Rev Neurol (Paris); 1978 Feb; 134(2):141-9. PubMed ID: 29330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind evaluation of lysivane in the treatment of Parkinson's disease.
    Strang RR
    Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485
    [No Abstract]   [Full Text] [Related]  

  • 14. [The treatment of Parkinson's syndrome with L-dopa].
    Völler GW; Kerstan J
    Nervenarzt; 1970 Mar; 41(3):138-44. PubMed ID: 5447886
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled trial of amantadine hydrochloride in Parkinson's disease.
    Jorgensen PB; Bergin JD; Haas L; Cuningham JA; Morah DD; Pollock M; Robinson RG; Spears GF
    N Z Med J; 1971 May; 73(468):263-7. PubMed ID: 4932146
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586
    [No Abstract]   [Full Text] [Related]  

  • 18. [Amantadine treatment in Parkinson's disease].
    Boman K; Kivalo E; Porras J
    Nord Med; 1970 Nov; 84(48):1518-20. PubMed ID: 4922228
    [No Abstract]   [Full Text] [Related]  

  • 19. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
    Carolei A; Meco G; Casacchia M; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):475-8. PubMed ID: 16441
    [No Abstract]   [Full Text] [Related]  

  • 20. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.